Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
Quick Read LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioid-free label claim. Phase 3 trials launching …